Aisha Mobashar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aisha Mobashar has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Ashfaq Ahmad
Department of Pharmacy Practice, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin 39524, Saudi Arabia
2 shared publications Saleh Alfuraih
Department of Pharmacology and Toxicology, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia
2 shared publications- Abdel-Rhman Zakaria Gaafar
Department of Botany and Microbiology, College of Science King Saud University Riyadh Saudi Arabia
1 shared publication Abdulaziz H. Alanazi
Department of Clinical Practice, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia
1 shared publicationAbdulelah Alhazza
Department of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia
1 shared publicationAli F. Almutairy
Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (9)
Unraveling the Anti‐Arthritic Potential of Bioactive Compounds From Melaleuca alternifolia Oil: Integrated In Vivo, Molecular Docking, and Network Pharmacology Insights
Rheumatoid arthritis (RA) is a chronic inflammatory condition that affects millions of people globally, often leading to morbidity. Recent research highlights the potential of natural products in managing arthritis symptoms and modifying disease progression. Among these, Melaleuca alternifolia oil (MAO) has emerged as a promising therapeutic option due to its anti‐inflammatory and analgesic properties. A total of 36 Sprague–Dawley rats weighing between 200 and 220 g were divided into six groups ( n = 6). On day 0, arthritis was induced by CFA. On day 8, treatment started and lasted till day 28. Paw edema and arthritic score were measured. Moreover, hematological, histological, and biochemical parameters were evaluated. The mRNA expression levels of anti‐inflammatory cytokine IL‐4 and pro‐inflammatory cytokines such as TNF‐α, IL‐6, NF‐κB, and IL‐1β were measured using real‐time polymerase chain reaction (qPCR). ELISA was used to detect PGE2 levels. Network pharmacology was used to evaluate the hub genes between the phytocompounds and rheumatoid arthritis. Molecular docking and scoring calculations were done for the top matched hub genes for moderate confirmations between phytocompounds and targets. GC–MS analysis was also performed to identify potential anti‐inflammatory constituents present in the plant oil. Treatment with MAO effectively reduced paw edema and swelling. Histopathological examinations demonstrated significant improvement in the treatment groups. Biochemical parameters such as creatinine, urea, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) did not significantly alter, and hematological parameters such as red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb), and platelet count were restored in the treated group. The mRNA expression of anti‐inflammatory cytokines, including IL‐4, was upregulated, and pro‐inflammatory biomarkers such as TNF‐α, IL‐1β, IL‐6, and NF‐κB were significantly downregulated in the arthritic control group. Furthermore, treatment with MAO significantly reduced PGE2 levels. Network pharmacology indicated the hub genes and several biological processes, molecular functions, cellular components, and KEGG pathways that are involved in rheumatoid arthritis. Molecular docking was performed against hub genes such as AKT1, BCL‐2, MAPK3, and MMP9 that are involved in various pro‐inflammatory cytokine formation and pathophysiology of rheumatoid arthritis. GC–MS analysis of the plant's oil revealed the presence of numerous anti‐inflammatory and antirheumatic phytochemicals. MAO possesses considerable anti‐arthritic properties by downregulating pro‐inflammatory biomarkers such as IL‐1β, NF‐κB, IL‐6, TNF‐α, and upregulating anti‐inflammatory IL‐4. Further investigations are needed to explore its potential as a natural therapeutic option for treating RA.
- 23 September 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (9)
Open AccessUnraveling the Anti‐Arthritic Potential of Bioactive Compounds From Melaleuca alternifolia Oil: Integrated In Vivo, Molecular Docking, and Network Pharmacology Insights
Rheumatoid arthritis (RA) is a chronic inflammatory condition that affects millions of people globally, often leading to morbidity. Recent research highlights the potential of natural products in managing arthritis symptoms and modifying disease progression. Among these, Melaleuca alternifolia oil (MAO) has emerged as a promising therapeutic option due to its anti‐inflammatory and analgesic properties. A total of 36 Sprague–Dawley rats weighing between 200 and 220 g were divided into six groups ( n = 6). On day 0, arthritis was induced by CFA. On day 8, treatment started and lasted till day 28. Paw edema and arthritic score were measured. Moreover, hematological, histological, and biochemical parameters were evaluated. The mRNA expression levels of anti‐inflammatory cytokine IL‐4 and pro‐inflammatory cytokines such as TNF‐α, IL‐6, NF‐κB, and IL‐1β were measured using real‐time polymerase chain reaction (qPCR). ELISA was used to detect PGE2 levels. Network pharmacology was used to evaluate the hub genes between the phytocompounds and rheumatoid arthritis. Molecular docking and scoring calculations were done for the top matched hub genes for moderate confirmations between phytocompounds and targets. GC–MS analysis was also performed to identify potential anti‐inflammatory constituents present in the plant oil. Treatment with MAO effectively reduced paw edema and swelling. Histopathological examinations demonstrated significant improvement in the treatment groups. Biochemical parameters such as creatinine, urea, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) did not significantly alter, and hematological parameters such as red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb), and platelet count were restored in the treated group. The mRNA expression of anti‐inflammatory cytokines, including IL‐4, was upregulated, and pro‐inflammatory biomarkers such as TNF‐α, IL‐1β, IL‐6, and NF‐κB were significantly downregulated in the arthritic control group. Furthermore, treatment with MAO significantly reduced PGE2 levels. Network pharmacology indicated the hub genes and several biological processes, molecular functions, cellular components, and KEGG pathways that are involved in rheumatoid arthritis. Molecular docking was performed against hub genes such as AKT1, BCL‐2, MAPK3, and MMP9 that are involved in various pro‐inflammatory cytokine formation and pathophysiology of rheumatoid arthritis. GC–MS analysis of the plant's oil revealed the presence of numerous anti‐inflammatory and antirheumatic phytochemicals. MAO possesses considerable anti‐arthritic properties by downregulating pro‐inflammatory biomarkers such as IL‐1β, NF‐κB, IL‐6, TNF‐α, and upregulating anti‐inflammatory IL‐4. Further investigations are needed to explore its potential as a natural therapeutic option for treating RA.
- Open Access
- 2 July 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (11) , 2393-2406
Indole-3-carbinol attenuates DNCB-induced atopic dermatitis in mice by reducing inflammation and IL-4/IL-13 expression
Atopic dermatitis (AD), commonly known as atopic eczema, is a chronic inflammatory skin disease. Indole-3-carbinol (I3C), a phytochemical naturally occurring in Brassica vegetables, has been traditionally used in folk medicine for inflammatory and metabolic disorders. This study investigated the immunomodulatory and anti-inflammatory effects of I3C in a mouse model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis. Atopic dermatitis was induced by DNCB sensitization on days 0 and 3. Following disease confirmation on day 7, mice received daily oral or topical administrations of I3C or prednisolone from day 7 to day 19. Macroscopic evaluations included dorsal skin and ear thickness measurements. Histopathological changes were assessed using hematoxylin and eosin staining, and hematological parameters were also analyzed. Gene expression of interleukin (IL)-4 and IL-13 in ear tissue was quantified by real-time polymerase chain reaction (RT-qPCR). Computational molecular docking was performed to determine I3C's affinity for both cytokines. The data indicated that I3C attenuated DNCB-induced AD-like symptoms following both oral and topical administration. Treatment with I3C also resulted in reduced ear thickness. Hematological analysis revealed significantly decreased total leukocyte counts (TLC) and a general downward numerical trend in differential leukocyte count (DLC) parameters in I3C-treated groups. Histopathological evaluation confirmed that I3C ameliorated skin thickening and reduced inflammatory cell infiltration. Furthermore, IL-4 and IL-13 expression levels were decreased in I3C-treated groups. Molecular docking analysis demonstrated moderate binding affinities of -5.1 kcal/mol and -5.3 kcal/mol with IL-4 and IL-13, respectively. In conclusion, findings from this exploratory study suggest that I3C treatment ameliorated DNCB-induced atopic dermatitis in mice, evidenced by reductions in ear thickness and IL-4/IL-13 mRNA expression. Molecular docking analysis demonstrated moderate binding affinities of I3C toward IL-4 and IL-13, providing supportive evidence of potential ligand-protein interactions.
- 2 July 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (11) , 2393-2406
Open AccessIndole-3-carbinol attenuates DNCB-induced atopic dermatitis in mice by reducing inflammation and IL-4/IL-13 expression
Atopic dermatitis (AD), commonly known as atopic eczema, is a chronic inflammatory skin disease. Indole-3-carbinol (I3C), a phytochemical naturally occurring in Brassica vegetables, has been traditionally used in folk medicine for inflammatory and metabolic disorders. This study investigated the immunomodulatory and anti-inflammatory effects of I3C in a mouse model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis. Atopic dermatitis was induced by DNCB sensitization on days 0 and 3. Following disease confirmation on day 7, mice received daily oral or topical administrations of I3C or prednisolone from day 7 to day 19. Macroscopic evaluations included dorsal skin and ear thickness measurements. Histopathological changes were assessed using hematoxylin and eosin staining, and hematological parameters were also analyzed. Gene expression of interleukin (IL)-4 and IL-13 in ear tissue was quantified by real-time polymerase chain reaction (RT-qPCR). Computational molecular docking was performed to determine I3C's affinity for both cytokines. The data indicated that I3C attenuated DNCB-induced AD-like symptoms following both oral and topical administration. Treatment with I3C also resulted in reduced ear thickness. Hematological analysis revealed significantly decreased total leukocyte counts (TLC) and a general downward numerical trend in differential leukocyte count (DLC) parameters in I3C-treated groups. Histopathological evaluation confirmed that I3C ameliorated skin thickening and reduced inflammatory cell infiltration. Furthermore, IL-4 and IL-13 expression levels were decreased in I3C-treated groups. Molecular docking analysis demonstrated moderate binding affinities of -5.1 kcal/mol and -5.3 kcal/mol with IL-4 and IL-13, respectively. In conclusion, findings from this exploratory study suggest that I3C treatment ameliorated DNCB-induced atopic dermatitis in mice, evidenced by reductions in ear thickness and IL-4/IL-13 mRNA expression. Molecular docking analysis demonstrated moderate binding affinities of I3C toward IL-4 and IL-13, providing supportive evidence of potential ligand-protein interactions.
- Open Access
- 10 March 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (9) , 1639-1651
Geraniol alleviates DNCB-induced atopic dermatitis in mice by downregulating IL-4/IL-13 and reducing inflammation
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by recurrent itching, predominantly affecting children but also impacting adults. Geraniol, a monoterpene alcohol found in various aromatic plant-based essential oils, possesses a pleasant rose-like scent. This study aimed to investigate the therapeutic potential of geraniol in a mouse model of atopic dermatitis by elucidating its anti-inflammatory and immunomodulatory properties. Mice were subjected to 2% 2,4-Dinitrochlorobenzene (DNCB) to induce AD, and treated with both oral and topical administrations of prednisolone and geraniol from day 7 to day 19. Macroscopic assessments of ear and dorsal skin, as well as ear thickness, were conducted on days 0, 7, and 19. Total leukocyte count (TLC) and differential leukocyte count (DLC) were measured in blood samples using an automatic hematology analyzer. Ear tissues were analyzed for mRNA expression levels of IL-4 and IL-13 via reverse transcription quantitative polymerase chain reaction (RT-qPCR), and molecular docking studies were performed to evaluate the binding affinity of geraniol to these cytokines. Histopathological examination using hematoxylin and eosin staining was conducted on ear and dorsal skin tissues to assess eosinophil and mast cell infiltration, as well as epidermal thickness. The results demonstrated that both oral and topical geraniol significantly alleviated AD-like symptoms. Geraniol treatment led to a reduction in DLC and TLC levels in the blood, as well as downregulation of IL-4 and IL-13 expression in ear tissue. In silico studies revealed that geraniol exhibited moderate binding affinities of -4.5 kcal/mol with IL-4 and -4.9 kcal/mol with IL-13. Histopathological analysis indicated a reduction in epidermal thickness and infiltration of mast cells and eosinophils in geraniol-treated mice. In conclusion, geraniol effectively alleviated atopic dermatitis in mice by reducing clinical scores, inflammatory cell infiltration, epidermal thickening, and regional downregulation of IL-4 and IL-13 mRNA expression. The in silico docking studies support the hypothesis of a potential Th2-modulatory effect of geraniol.
- 10 March 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (9) , 1639-1651
Open AccessGeraniol alleviates DNCB-induced atopic dermatitis in mice by downregulating IL-4/IL-13 and reducing inflammation
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by recurrent itching, predominantly affecting children but also impacting adults. Geraniol, a monoterpene alcohol found in various aromatic plant-based essential oils, possesses a pleasant rose-like scent. This study aimed to investigate the therapeutic potential of geraniol in a mouse model of atopic dermatitis by elucidating its anti-inflammatory and immunomodulatory properties. Mice were subjected to 2% 2,4-Dinitrochlorobenzene (DNCB) to induce AD, and treated with both oral and topical administrations of prednisolone and geraniol from day 7 to day 19. Macroscopic assessments of ear and dorsal skin, as well as ear thickness, were conducted on days 0, 7, and 19. Total leukocyte count (TLC) and differential leukocyte count (DLC) were measured in blood samples using an automatic hematology analyzer. Ear tissues were analyzed for mRNA expression levels of IL-4 and IL-13 via reverse transcription quantitative polymerase chain reaction (RT-qPCR), and molecular docking studies were performed to evaluate the binding affinity of geraniol to these cytokines. Histopathological examination using hematoxylin and eosin staining was conducted on ear and dorsal skin tissues to assess eosinophil and mast cell infiltration, as well as epidermal thickness. The results demonstrated that both oral and topical geraniol significantly alleviated AD-like symptoms. Geraniol treatment led to a reduction in DLC and TLC levels in the blood, as well as downregulation of IL-4 and IL-13 expression in ear tissue. In silico studies revealed that geraniol exhibited moderate binding affinities of -4.5 kcal/mol with IL-4 and -4.9 kcal/mol with IL-13. Histopathological analysis indicated a reduction in epidermal thickness and infiltration of mast cells and eosinophils in geraniol-treated mice. In conclusion, geraniol effectively alleviated atopic dermatitis in mice by reducing clinical scores, inflammatory cell infiltration, epidermal thickening, and regional downregulation of IL-4 and IL-13 mRNA expression. The in silico docking studies support the hypothesis of a potential Th2-modulatory effect of geraniol.